On clinicaltrials.gov it lists the primary completion date as March 2022. Hopefully they will be keeping shareholders somewhat informed because any larger organization who wants to know how the trial is progressing will not have much problem obtaining that information one way or another, since the trial is small and open label. 

Further to Pfizer's Paxlovid not mixing well with some other drugs, I read that one of those drug classes is statins. That would seem to help the RVX opportunity should this covid trial be successful. 

There has been some talk here (as always) about future financing.  I think Don is likely now waiting to see how this trial goes. With a successful covid trial the stock price should be meaningfully higher thus creating a better financing environment for the company. Hopefully he can also finally complete some of the deals/partnership that he has been talking about for sooooo long. He says in the radio spot that the company "knows where all the low hanging fruit is."